Novocure (NVCR) Offers Positive Case Study on Second-Gen Optune System
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Stocks hit by tech slide; yen flails at intervention zone
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen hits fresh 34-year lows against dollar ahead of BOJ meeting
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Novocure Converts More Than 500 U.S. Patients to Second Generation Optune within Four Weeks of FDA Approval on July 13
August 16, 2016 7:00 AM EDTThe second generation device is less than half the weight and half the size of the first generation Optune System
ST. HELIER, Jersey--(BUSINESS WIRE)-- Before starting treatment with Optune in October 2015, Michael Olson, 39, of Beaumont, Texas, worried about how hed incorporate the treatment into his life and practice as a dentist. It wasnt long before he started feeling comfortable with the device, and he says half of his patients dont notice he is wearing it.
This Smart News Release features multimedia. View the full release... More
